BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Genelux Corporation Announces Treatment of First Patient in Phase I/II Clinical Trial of GL-ONC1 in Advanced Peritoneal Cavity Cancers


5/31/2012 8:23:10 AM

SAN DIEGO, CA--(Marketwire - May 31, 2012) - Genelux Corporation, a privately-held clinical-stage biopharmaceutical company focused on development and commercialization of best-in-class, vaccinia-virus-based oncolytic viral therapies and companion diagnostics for cancer, today announced that the first patient was treated on April 30, 2012 in a Phase I/II clinical trial of GL-ONC1 in patients with advanced peritoneal cavity cancers. The safety and dose-escalation study will evaluate GL-ONC1 administered intra-peritoneally as a single agent therapy, and will include a number of possible of cancer types -- potentially gastric, colon, liver, kidney, ovarian and pancreatic cancer, among others. Importantly, this is the first time that a vaccinia-based oncolytic viral therapy was administered to a human cancer patient in Germany.

"GL-ONC1, our leading product candidate, has been well-tolerated and shown encouraging results in early human trials against a number of solid tumor cancers. It is based on a novel product platform that delivers therapeutic and diagnostic constructs directly to tumors without harming healthy tissues or cells," said Dr. Aladar A. Szalay, founder and CEO of Genelux Corporation. "In this trial, we hope further to evaluate GL-ONC1's safety profile, dosing scheme and anti-tumor effects specifically within the peritoneal body cavity, and to explore whether, for such cancers, intra-peritoneal administration is the most effective means to reach and kill these cancer cells or tumor types."

The study is being conducted at University Hospital Tuebingen, in Tuebingen Germany, and may enroll up to 30 patients across two phases. Once a maximum tolerated dose (MTD) or Recommended Dose (RD) is determined for patients in the Phase I portion of the study, additional patients may be enrolled to conclude the Phase II portion of the trial. The endpoints of the trial include safety, dose optimization and anti-tumor effects as measured by RECIST and Choi criteria. For more information about the trial, please visit www.clinicaltrials.gov.

About Genelux Corporation

Headquartered in San Diego, California, Genelux Corporation is a privately held, clinical stage biopharmaceutical company dedicated to fundamentally changing the way in which cancer is diagnosed and treated. The company has developed a proprietary oncolytic virus-based technology platform featuring a companion optical imaging [luminescent/fluorescent] diagnostic capability on a therapeutic, replication-competent Lister strain vaccinia virus backbone. It is designed to selectively find and kill cancer cells without harming healthy tissues or cells. The platform can also be "customized" by inserting desired genes to effectively treat a variety of cancers and cancer-related conditions. The company is also incorporating advanced diagnostic deep-tissue imaging technologies into its viral platform to enable highly specific visualization of tumors and circulating cancer cells. GL-ONC1, the company's lead oncology product candidate, is an attenuated (Lister strain) vaccinia virus currently under evaluation in human clinical trials in Europe where they are officially sponsored by Genelux GmbH, a wholly owned subsidiary of Genelux Corporation. Additional US- and European-based trials are set to begin imminently. For more information please visit http://www.genelux.com.

Genelux Forward-Looking Statement

Statements made about Genelux Corporation, other than statements of historical fact, reflect Management's current beliefs and assumptions founded on the data and information currently available to us. Statements of the company's progress, results, timing of pre-clinical and clinical trials and projections for product pipelines are examples of forward-looking statements. By definition, such undertakings involve risks, uncertainties and assumptions, and are subject to a number of such factors that could cause actual results to differ substantially from statements made, including but not limited to: risks associated with the success of clinical trials, research and development programs, regulatory approval processes for clinical trials, competitive technologies and products, patents, inception and/or continuation of corporate and other strategic partnerships and the need for additional funding or financing.


Contacts:

Amy Berry
RCI Partners
415-793-2258
Email Contact

Richard Roose
RCI Partners
415-202-4445
Email Contact



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->